Featured Research Search Results
IGNITE-TX - Identifying Individuals for Genetic Testing for Familial Cancer
Clinicaltrials.gov identifier:
NCT07318363
Prevention
People with a genetic mutation in BRCA1, BRCA2 or Lynch syndrome who have relatives who have not been tested
Phase 3
Virtual Exercise Classes for Adult Cancer Survivors (SURGE)
Clinicaltrials.gov identifier:
NCT07290309
Quality of Life
Exercise study for people diagnosed within the past 5 years
Treating Advanced MSI-High or dMMR Cancers Using the Targeted Therapy MOMA-341 Given Alone or In Combination with Standard Therapies
Clinicaltrials.gov identifier:
NCT06974110
Treatment
Treatment study for people with advanced or metastatic cancers
Phase 1
REKINDLE: Your Ability to Cope With a Life-Changing Medical Diagnosis
Clinicaltrials.gov identifier:
NCT07002034
Quality of Life
Study for those experiencing mental health struggles due to a diagnosis of cancer or other medical illness
Phase 2
Multi-Cancer Detection Blood Tests in Adults Without Cancer: Vanguard Study
Clinicaltrials.gov identifier:
NCT06995898
Prevention
A study testing two multi-cancer detection blood tests in people who do not have cancer
Psilocybin Therapy in Advanced Cancer
Clinicaltrials.gov identifier:
NCT05398484
Quality of Life
Study for people with advanced cancer
Phase 2
A 5-minute Patient and Caregiver survey to share experiences with immunotherapy and any short-term or long-term side effects
Surveys, Registries, Interviews
Survey on immunotherapy to share experiences, including side effects and whether they were resolved or not
Testing the Drug CX-5461 for Treating Metastatic Solid Tumors
Clinicaltrials.gov identifier:
NCT06606990
Treatment
Phase 1 study for treatment of advanced solid tumors
Phase 1
Using the Drug Daraxonrasib in Surgically Removed Pancreatic Cancer (RASolute 304)
Clinicaltrials.gov identifier:
NCT07252232
Treatment
Study for pancreatic cancer treatment after surgery and chemotherapy
Phase 3
Comparing Daraxonrasib With or Without Chemotherapy to Chemotherapy Alone for First-Line Treatment of Metastatic Pancreatic Cancer (Rasolute 303)
Clinicaltrials.gov identifier:
NCT07491445
Treatment
Study for First-Line Treatment of Metastatic Pancreatic Cancer
Phase 3
Testing a Targeted Therapy ETX-19477 to Treat Advanced Solid Tumors in People with a BRCA2 Mutation (ERADIC8)
Clinicaltrials.gov identifier:
NCT06395519
Treatment
Treatment study for people with advanced breast, colorectal, endometrial, ovarian or pancreatic cancer
Phase 1/2
Study of a New Oral Medication, Daraxonrasib After Surgery to Help Prevent Pancreatic Cancer from Returning
Clinicaltrials.gov identifier:
NCT07252232
Treatment
Phase 3 treatment trial for pancreatic cancer that was removed by surgery
Phase 3
Comparing Two Vaccine Treatments With Immunotherapy for Pancreatic Cancer Before and After Surgery
Clinicaltrials.gov identifier:
NCT06782932
Treatment
Treatment study for newly diagnosed pancreatic cancer that can be removed with surgery and who have not yet received treatment
Phase 1/2
Using a Blood Test to Detect Early Cancer Recurrence After Treatment (ORACLE)
Clinicaltrials.gov identifier:
NCT05059444
Treatment
Post-treatment study to monitor for recurrence
An Early Detection and Prevention Study for People with an Increased Risk of Cancer (InAdvance)
Clinicaltrials.gov identifier:
NCT05463796
Prevention
Study for people at risk of cancer, including previvors, survivors and family members
Treating Advanced Solid Tumors with Targeted Therapies Called RAS(ON) Inhibitors Combined With the Targeted Immunotherapy Ivonescimab
Clinicaltrials.gov identifier:
NCT07397338
Treatment
Treatment study for solid tumors with a RAS mutation
Phase 1/2
The EASE Study: Helping People with Advanced Cancer Cope with Fear of Cancer Progression
Clinicaltrials.gov identifier:
NCT07636200
Quality of Life
Quality of life study for people with advanced cancer experiencing anxiety
Treating Advanced Solid Tumors with a KRAS G12C Mutation Using Targeted Therapies Called RAS(ON) Inhibitors
Clinicaltrials.gov identifier:
NCT06128551
Treatment
Treatment study for advanced colorectal, pancreatic or lung cancer with a KRAS G12C mutation
Phase 1/2